Objectives: ANCA-associated vasculitis (AAV) can affect all age groups. We aimed to show that differences in disease presentation and 6 month outcome between younger- A nd older-onset patients are still incompletely understood. Methods: We included patients enrolled in the Diagnostic and Classification Criteria for Primary Systemic Vasculitis (DCVAS) study between October 2010 and January 2017 with a diagnosis of AAV. We divided the population according to age at diagnosis: <65 years or ≥65 years. We adjusted associations for the type of AAV and the type of ANCA (anti-MPO, anti-PR3 or negative). Results: A total of 1338 patients with AAV were included: 66% had disease onset at <65 years of age [female 50%; mean age 48.4 years (s.d. 12.6)] and 34% had disease onset at ≥65 years [female 54%; mean age 73.6 years (s.d. 6)]. ANCA (MPO) positivity was more frequent in the older group (48% vs 27%; P = 0.001). Younger patients had higher rates of musculoskeletal, cutaneous and ENT manifestations compared with older patients. Systemic, neurologic,cardiovascular involvement and worsening renal function were more frequent in the older-onset group. Damage accrual, measured with the Vasculitis Damage Index (VDI), was significantly higher in older patients, 12% of whom had a 6 month VDI ≥5, compared with 7% of younger patients (P = 0.01). Older age was an independent risk factor for early death within 6 months from diagnosis [hazard ratio 2.06 (95% CI 1.07, 3.97); P = 0.03]. Conclusion: Within 6 months of diagnosis of AAV, patients >65 years of age display a different pattern of organ involvement and an increased risk of significant damage and mortality compared with younger patients.

Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes / Monti S.; Craven A.; Klersy C.; Montecucco C.; Caporali R.; Watts R.; Merkel P.A.; Luqmani R.; Achilleos K.; Adler M.; Alba M.A.; Albert D.A.; Alibaz-Oner F.; Allcoat P.; Amano K.; Amarasuriya M.; Amudala N.A.; Andrews J.; Archer A.M.; Arimura Y.; Atukorala I.; Azevedo E.; Bajad S.; Baldwin C.; Barra L.J.; Baslund B.; Basu N.; Baykal M.; Berger C.; Berglin E.; Besada E.; Bhardwaj M.; Bischof A.; Blockmans D.; Blood J.; Draibe J.B.; Brand S.; Brandao M.; Bruce I.N.; Butler A.; Calabrese L.H.; Ferrer D.C.; Carette S.; Carmona D.; Ceunen H.; Chakravarty K.; Chapman P.T.; Chocova Z.; Chung S.A.; Ci W.; Cid M.C.; Clark T.M.; Clarkson M.R.; De Jesus Contreras-Rodriguez F.; Conway R.; Cooke K.; Viros X.C.; Cordeiro A.; Costa A.; Craven A.; Culfear K.; Daikeler T.; Danda D.; Das S.K.; Dasgupta B.; De Castro A.M.; Dehghan N.; Devassy R.; Dhindsa N.; Diamantopoulos A.P.; Direskeneli H.; Dobashi H.; Juan D.; Durrani M.; Edelsten C.; Eifert J.; Elhayek S.; Elsideeg S.; Endo T.; Erden A.; Erer B.; Eriksson P.; Erturk Z.; Espigol-Frigole G.; Felicetti M.; Ferraro A.; Ferro J.M.; Fifi-Mah A.; Flores-Suarez L.F.; Flossmann O.; Flynn D.; Fonseca J.E.; Foot J.; Foote M.; Forbess L.; Fujimoto S.; Fukuoka K.; Furtado C.; Furuta S.; Gaffo A.L.; Gallagher P.; Gao N.; Gatenby P.; Gendi N.; Geraldes R.; Gerits A.; Gioffredi A.; Gomples L.; Goncalves M.J.; Gondo P.; Graham A.; Grainger R.; Gray D.T.; Grayson P.C.; Griffiths L.; Guo Y.; Gupta R.; Gylling M.; Hajj-Ali R.A.; Hammam N.; Harigai M.; Hartley L.; Haslett J.; Hassan A.; Hatemi G.; Hellmich B.; Henckaerts L.; Henes J.C.; Hepburn J.; Herd V.; Hess C.; Hill C.; Hinojosa-Azaola A.; Hirahashi J.; Hirano F.; Hocevar A.; Holle J.; Hollinger N.; Homma S.; Howard T.; Hoyles R.K.; Hruskova Z.; Hutcheon G.; Ignacak M.; Igney-Oertel A.; Ikeda K.; Ikegaya N.; Jagadeesh S.; Jaquith J.; Jayne D.R.W.; Jewell T.; Jones C.; Joshi A.; Kalyoncu U.; Kamall S.; Kamath S.; Lai K.S.; Kaname S.; Kanchinadham S.; Karadag O.; Karube M.; Kaszuba M.; Kaur R.; Kawakami T.; Kawashima S.; Khalidi N.; Khan A.; Kikuchi M.; Kilic L.; Kimura M.; King M.J.; Klapa S.; Klocke R.; Kobayashi T.; Kobayashi S.; Komagata Y.; Kronbichler A.; Kuczia P.; Kumar M.S.; Kurosawa M.; Lamprecht P.; Langford C.A.; Lanyon P.; Laversuch C.; Lee S.J.; Leoni S.; Li J.; Liang K.; Liang P.; Liao H.; Lee L.A.; Luqmani R.A.; Lyle A.; Macdonald M.; Mackie S.L.; Madden L.; Magliano M.; Makino H.; Makol A.; Malaiya R.; Malaviya A.; Manthri R.; Maritati F.; Da Silva A.M.; Mason J.C.; Matara C.; Matsui K.; Matteson E.L.; Mcbride D.; Mccullough K.; Mcgeoch L.; Mclaren J.; Mcmillian C.; Mendiratta N.; Menon A.; Merinopoulos D.; Merkel P.A.; Merkel P.; Messier S.; Micheletti R.G.; Mills K.; Milman N.; Minoda M.; Minz R.W.; Mock C.; Mohammad A.J.; Moiseev S.; Moitinho M.; Molloy E.; Monach P.A.; Montgomery M.; Moosig F.; Moradizadeh M.; Morgan M.; Morgan A.W.; Morgan A.-M.; Muir A.; Mukhtyar C.; Muller A.; Muratore F.; Muso E.; Nada R.; Nakajima H.; Nakajima T.; Nakano H.; Nandagudi A.; Neumann T.; Ng Y.F.; Ng K.H.; Nogueira E.L.; Nolkha N.; Nordstrom D.; Novikov P.; Nugaliyadde A.; O'donnell J.L.; O'donoghue J.; O'neill L.; O'riordan E.; Oatley M.; Okubo K.; Oliva E.; Oshikawa H.; Ota Y.; Padoan R.; Pagnoux C.; Pan L.; Panaritis K.; Park J.K.; Patel S.; Patil P.; Pazzola G.; Peall A.; Pearce F.; Pehlevan S.; Pereira L.; Pettersson T.; Pineau C.A.; Pirila L.; Poglodek B.; Ponte C.; Prieto-Gonzalez S.; Priya S.R.; Purewal B.; Purschke S.; Putaala J.; Quickert S.; Quincey V.; Raghuvanshi S.; Rajasekhar L.; Ranganathan D.; Rathi M.; Rees D.; Rees F.; Renken U.; Restuccia G.; Rhee R.L.; Rice B.; Robins D.; Robson J.; Rodrigues M.; Romao V.C.; Rotar C.; Ruediger C.; Rutgers A.; Sa A.C.; Saavedra M.J.; Sada K.-E.; Sahbudin I.; Salvarani C.; Sandhu N.; Santos E.; Sato Y.; Schafer V.S.; Schiavon F.; Schmidt W.A.; Segelmark M.; Shahin A.; Sharma A.; Shotton J.; Silva C.; Singer O.G.; Sivasuthan G.; Smolen S.; Solanich-Moreno X.; Boixader L.S.; Song Y.W.; Springer J.; Sreih A.G.; Srivastava R.; Stamp L.K.; Stevens R.; Strbian D.; Sugino K.; Sunderkotter C.; Suppiah R.; Suzuki K.; Suzuki K.; Szekanecz Z.; Sznajd J.; Taimen K.; Tak P.P.; Takeuchi T.; Takizawa N.; Tames L.; Tan B.E.; Tanaka M.; Tang M.W.; Tatlisumak T.; Tesar V.; Thomas A.; Tian X.; Tokunaga K.; Tombetti E.; Tomsic M.; Toz B.; Tsukamoto T.; Uchida S.; Unal A.U.; Urban M.L.; Usui J.; Vaglio A.; Venkatachalam S.; Vermaak E.; Viswanath V.; Wada T.; Wagh S.; Wallace D.J.; Walters G.; Walz B.; Wan J.; Wang T.; Wang G.; Warrington K.J.; Watts R.A.; Wawrzycka-Adamczyk K.; Weeratunga P.; Weisman M.H.; Wickramasinghe S.; Williams M.; Williams M.; Wojcik K.; Woodruff L.; Xenitidis T.; Yamada H.; Yamagata K.; Yee C.-S.; Yoon M.; Yoshida K.; Yoshifuji H.; Ytterberg S.R.; Yumura W.; Zayed H.; Zeng X.; Zhao M.-H.; Zugaj A.; Zuk J.. - In: RHEUMATOLOGY. - ISSN 1462-0324. - ELETTRONICO. - 60:(2021), pp. 617-628. [10.1093/rheumatology/keaa215]

Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes

Urban M. L.;Vaglio A.;
2021

Abstract

Objectives: ANCA-associated vasculitis (AAV) can affect all age groups. We aimed to show that differences in disease presentation and 6 month outcome between younger- A nd older-onset patients are still incompletely understood. Methods: We included patients enrolled in the Diagnostic and Classification Criteria for Primary Systemic Vasculitis (DCVAS) study between October 2010 and January 2017 with a diagnosis of AAV. We divided the population according to age at diagnosis: <65 years or ≥65 years. We adjusted associations for the type of AAV and the type of ANCA (anti-MPO, anti-PR3 or negative). Results: A total of 1338 patients with AAV were included: 66% had disease onset at <65 years of age [female 50%; mean age 48.4 years (s.d. 12.6)] and 34% had disease onset at ≥65 years [female 54%; mean age 73.6 years (s.d. 6)]. ANCA (MPO) positivity was more frequent in the older group (48% vs 27%; P = 0.001). Younger patients had higher rates of musculoskeletal, cutaneous and ENT manifestations compared with older patients. Systemic, neurologic,cardiovascular involvement and worsening renal function were more frequent in the older-onset group. Damage accrual, measured with the Vasculitis Damage Index (VDI), was significantly higher in older patients, 12% of whom had a 6 month VDI ≥5, compared with 7% of younger patients (P = 0.01). Older age was an independent risk factor for early death within 6 months from diagnosis [hazard ratio 2.06 (95% CI 1.07, 3.97); P = 0.03]. Conclusion: Within 6 months of diagnosis of AAV, patients >65 years of age display a different pattern of organ involvement and an increased risk of significant damage and mortality compared with younger patients.
2021
60
617
628
Monti S.; Craven A.; Klersy C.; Montecucco C.; Caporali R.; Watts R.; Merkel P.A.; Luqmani R.; Achilleos K.; Adler M.; Alba M.A.; Albert D.A.; Alibaz-...espandi
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1237441
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 23
social impact